A composition in the form of an extract or a product thereof, said composition comprising (i) at least one cannabinoid; (ii) a total primary terpene content forming at least 40% by weight of the total amount of terpenes in the composition; (iii) at least 5% by weight of a non-cannabinoid, non-terpene carrier, wherein said carrier comprises less than 5% cellulose by weight; (iv) less than 5% by weight glycol; and (v) less than 5% by weight water; for use in treating a condition selected from the group consisting of pain, anxiety, depression, a sleep disorder, autism and autism spectrum disorder by oral administration, wherein a) when said condition is pain, said at least one cannabinoid comprises THC and/or CBD; said primary terpene is selected from the group consisting of beta-myrcene, linalool, beta-caryophyllene, humulene, eucalyptol, beta-amyrin and combinations thereof; and a total terpenes to total cannabinoids weight/weight ratio in said composition is between 0.05:1 and 0.5:1; b) when said condition is depression, said at least one cannabinoid comprises CBD; said primary terpene is selected from the group consisting of limonene, linalool, beta-myrcene, beta-caryophyllene and combinations thereof; and a total terpenes to total cannabinoids weight/weight ratio in said composition is between 0.1:1 and 0.5:1; c) when said condition is anxiety, said at least one cannabinoid comprises CBD; said primary terpene is selected from the group consisting of limonene, linalool, beta-caryophyllene and combinations thereof and a total terpenes to total cannabinoids weight/weight ratio in said composition is between 0.1:1 and 0.5:1; d) when said condition is ASD, said at least one cannabinoid comprises CBD; said primary terpene is selected from the group consisting of limonene, beta-caryophyllene, caryophyllene oxide, pinene, beta- myrcene, humulene, citronellol, eucalyptol and combinations thereof; and a total terpenes to total cannabinoids weight/weight ratio in said composition is between 0.05:1 and 0.5:1; and e) when said condition is a sleep disorder, said at least one cannabinoid comprises CBD; said primary terpene is selected from the group consisting of linalool, beta-myrcene, beta-caryophyllene and combinations thereof; and a total terpenes to total cannabinoids weight/weight ratio in said composition is between 0.1:1 and 0.5:1. (i) at least one cannabinoid; (ii) a total primary terpene content forming at least 40% by weight of the total amount of terpenes in the composition; (iii) at least 5% by weight of a non-cannabinoid, non-terpene carrier, wherein said carrier comprises less than 5% cellulose by weight; (iv) less than 5% by weight glycol; and (v) less than 5% by weight water; a) when said condition is pain, said at least one cannabinoid comprises THC and/or CBD; said primary terpene is selected from the group consisting of beta-myrcene, linalool, beta-caryophyllene, humulene, eucalyptol, beta-amyrin and combinations thereof; and a total terpenes to total cannabinoids weight/weight ratio in said composition is between 0.05:1 and 0.5:1; b) when said condition is depression, said at least one cannabinoid comprises CBD; said primary terpene is selected from the group consisting of limonene, linalool, beta-myrcene, beta-caryophyllene and combinations thereof; and a total terpenes to total cannabinoids weight/weight ratio in said composition is between 0.1:1 and 0.5:1; c) when said condition is anxiety, said at least one cannabinoid comprises CBD; said primary terpene is selected from the group consisting of limonene, linalool, beta-caryophyllene and combinations thereof and a total terpenes to total cannabinoids weight/weight ratio in said composition is between 0.1:1 and 0.5:1; d) when said condition is ASD, said at least one cannabinoid comprises CBD; said primary terpene is selected from the group consisting of limonene, beta-caryophyllene, caryophyllene oxide, pinene, beta- myrcene, humulene, citronellol, eucalyptol and combinations thereof; and a total terpenes to total cannabinoids weight/weight ratio in said composition is between 0.05:1 and 0.5:1; and e) when said condition is a sleep disorder, said at least one cannabinoid comprises CBD;